ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 1ÔÂ24ÈÕ£¬£¬£¬£¬Ô¶´óÒ½Ò©Ðû²¼Í¨¸æ£¬£¬£¬£¬Á¥Êô¹«Ë¾ÄϾ©°ÂÂÞÉúÎïÖÎÁÆÐÔÖ×ÁöÒßÃçARC01£¨A002£©µÄÐÂÒ©ÁÙ´²ÊÔÑéÉêÇ루IND£©»ñ¹ú¼ÒÒ©¼à¾ÖÅú×¼£¬£¬£¬£¬ÓÃÓÚÈËÀàÈéÍ·Áö²¡¶¾16ÐÍ£¨HPV-16£©ÑôÐÔµÄÍíÆÚ²»¿ÉÇгý»ò¸´·¢/×ªÒÆÐÔʵÌåÁö¡£¡£¡£¡£¡£
2. 1ÔÂ25ÈÕ£¬£¬£¬£¬Õ׿ÆÑÛ¿ÆÐû²¼£¬£¬£¬£¬BRIMOCHOL PF ¼°CARBACHOL PFµÄÐÂÒ©ÊÔÑéÉêÇ룬£¬£¬£¬×î½ü»ñÖйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú×¼¡£¡£¡£¡£¡£BRIMOCHOL PF¼°Carbachol PFΪ²»º¬·À¸¯¼ÁµÄÖðÈÕÒ»´ÎÍ«¿×µ÷ÀíµÎÑÛÒº£¬£¬£¬£¬ÓÃÓÚ½ÃÕýÒòÀÏ»¨ÑÛ¶øËðʧ½ü¾àÀëÊÓÁ¦µÄÁÆ·¨¡£¡£¡£¡£¡£
3. 1ÔÂ23ÈÕ£¬£¬£¬£¬¹ãÖÝ»ª½òÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾×ÔÖ÷Ñз¢µÄÈÜÁöϸ¾úÉ£ÃÀÍþ¿Ë?£¨SalMet-Vec?£©×¢Éä¼Á»ñµÃÃÀ¹úʳÎïºÍÒ©Îï¼àÊÓ¹ÜÀí¾Ö£¨FDA£©ÊÚÓèµÄ¿ìËÙͨµÀÈ϶¨£¬£¬£¬£¬ÓÃÓÚÖÎÁƼÈÍù½ÓÊܹýÖÁÉÙÁ½ÖÖÖÎÁƵÄ×ªÒÆÐÔ¹ÇѪÁö»¼Õß¡£¡£¡£¡£¡£
4. 1ÔÂ23ÈÕ£¬£¬£¬£¬¾ÝCDE¹ÙÍøÏÔʾ£¬£¬£¬£¬ÜõÐÅÉúÎQX005N ×¢ÉäÒº¡¹ÄâÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖ¡£¡£¡£¡£¡£±¾´Î¹«Ê¾¸ÃÒ©ÎïÉ걨µÄÌØÊâ×ʸñ˳Ӧ֢Ϊ£ºÄâÖÎÁƳÉÈËÖÐÖØ¶È½á½ÚÐÔÑ÷ÕÊÜÀíºÅ£ºCXSL2200010£©¡£¡£¡£¡£¡£
1. 1ÔÂ23ÈÕ£¬£¬£¬£¬GenEditÐû²¼ÓëÂÞÊÏÆìÏ»ùÒòÌ©¿Ë£¨Genentech£©¹«Ë¾´ïÓñ³ÉÃæµÄ¶àÄêÏàÖúºÍÔÊÐíÐÒ飬£¬£¬£¬½«Ê¹Óà GenEdit µÄ NanoGalaxy ƽ̨Ñз¢ÐÂÐÍÄÉÃ׿ÅÁ££¬£¬£¬£¬ÒÔ¿ª·¢ÓÃÓÚ×ÔÉíÃâÒßÐÔ¼²²¡µÄºËËáÒ©Îï¡£¡£¡£¡£¡£
1. ÔÚÒ»Ïî½ÒÏþÓÚ¡¶×ÔÈ»¡·×Ó¿¯µÄÐÂÑо¿ÖУ¬£¬£¬£¬°Ä´óÀûÑǵĿÆÑ§¼ÒÆÊÎöÁËBRCA2Ö°©Í»±äЯ´øÕߵĿµ½¡×éÖ¯Ñù±¾£¬£¬£¬£¬ÔÚÉÐδÉú³¤Îª°©Ö¢Ö®Ç°ÕÒ³öÁËÒ쳣ϸ°û¡ª¡ªÈéÏÙ°©µÄ¡°ÃÈÑ¿¡±¡£¡£¡£¡£¡£ÕâÒ»·¢Ã÷Òâζ×Å£¬£¬£¬£¬¹ØÓÚÈéÏÙ°©¸ßΣº¦µÄBRCA2Í»±äЯ´øÕߣ¬£¬£¬£¬½«¿É¿ª·¢ÐµÄÔ¤·ÀÐÔÖÎÁÆÒªÁì¡£¡£¡£¡£¡£
[1]Rachel Joyce et al., (2024) Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers. Nature Cell Biology Doi: https://doi.org/10.1038/s41556-023-01315-5
Ïà¹ØÐÂÎÅ